Careme Forum 17 Mar Pre-meeting survey

Dear Doctor, we kindly request your participation in a short pre-meeting survey. This survey will help us ensure that the workshop covers relevant topics aligned with your expertise and interests. The survey will only take a few minutes to complete.

Thank you for your commitment to this workshop, and we look forward to receiving your survey responses.

Name (optional)

Sector *

Specialty *

Q1. What are the main challenges or barriers you have encountered in initiating chronic kidney disease (CKD) screening in the primary care setting?
Please select all that apply:*

Q1. What are the main challenges or barriers you have encountered in initiating chronic kidney disease (CKD) screening in the primary care setting? Please select all that apply: *

Limited time/resources for screening
Lack of awareness among patients about CKD
Difficulty in identifying high-risk individuals
Limited access to diagnostic tests
Lack of guidelines or protocols for screening
Others

Q2. Within your clinical practice, do you usually perform estimated glomerular filtration rate (eGFR) testing, or proteinuria level testing, or both to diagnose CKD?*

Q2. Within your clinical practice, do you usually perform estimated glomerular filtration rate (eGFR) testing, or proteinuria level testing, or both to diagnose CKD? *

eGFR testing only
Proteinuria level test only
Both eGFR and proteinuria level testing

Q3. How frequently do you typically perform eGFR and proteinuria level testing in diabetic patients?*

Q3. How frequently do you typically perform eGFR and proteinuria level testing in diabetic patients? *

Never
Less than once a year
Once a year
More than once a year

Q4. What eGFR stage and proteinuria level do you commonly encounter in your clinical practice?
Please select one answer for each test:*

eGFR stage

eGFR stage

eGFR stage 1 (≥90 mL/min/1.73 m²)
eGFR stage 2 (60–89 mL/min/1.73 m²)
eGFR stage 3a (45–59 mL/min/1.73 m²)
eGFR stage 3b (30–44 mL/min/1.73 m²)
eGFR stage 4 (15–29 mL/min/1.73 m²)
eGFR stage 5 (<15 mL/min/1.73 m²)

Proteinuria level

Proteinuria level

Normal to mildly increased: uACR <30 mg/g; uPCR <150 mg/g
Moderately increased: uACR 30–299 mg/g; uPCR 150–499 mg/g
Severely increased: uACR ≥300 mg/g; uPCR ≥500 mg/g
I do not routinely check proteinuria levels

Q5. At what eGFR stage and proteinuria level would you initiate treatment?
Please select one answer for each test:*

eGFR stage

eGFR stage

eGFR stage 1 (≥90 mL/min/1.73 m²)
eGFR stage 2 (60–89 mL/min/1.73 m²)
eGFR stage 3a (45–59 mL/min/1.73 m²)
eGFR stage 3b (30–44 mL/min/1.73 m²)
eGFR stage 4 (15–29 mL/min/1.73 m²)
eGFR stage 5 (<15 mL/min/1.73 m²)
I will refer my patient to a specialist directly

Proteinuria level

Proteinuria level

Normal to mildly increased: uACR <30 mg/g; uPCR <150 mg/g
Moderately increased: uACR 30–299 mg/g; uPCR 150–499 mg/g
Severely increased: uACR ≥300 mg/g; uPCR ≥500 mg/g
I will refer my patient to a specialist directly

Q6. Please rate your confidence in managing patients with diabetic kidney disease using SGLT2 inhibitors: *

Not confident at all	Slightly confident	Moderately confident	Very confident	Extremely confident
Not confident at allItem #1 Not confident at all	Slightly confidentItem #1 Slightly confident	Moderately confidentItem #1 Moderately confident	Very confidentItem #1 Very confident	Extremely confidentItem #1 Extremely confident

Q7. Please rate your confidence in managing patients with non-diabetic chronic kidney disease using SGLT2 inhibitors: *

Not confident at all	Slightly confident	Moderately confident	Very confident	Extremely confident
Not confident at allItem #1 Not confident at all	Slightly confidentItem #1 Slightly confident	Moderately confidentItem #1 Moderately confident	Very confidentItem #1 Very confident	Extremely confidentItem #1 Extremely confident

Q8. What additional challenges related to the management of CKD would you like the speakers to address during this workshop?